You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Article metrics

Article menu
Commentary
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2025

AbstractFullPdf
Nov 2021604605219
Dec 202122923081
Jan 202212212675
Feb 2022777954
Mar 20229510054
Apr 202210110241
May 202211011649
Jun 202210310528
Jul 2022717322
Aug 202210710936
Sep 2022757751
Oct 202210310441
Nov 2022616134
Dec 2022474730
Jan 2023272928
Feb 2023616115
Mar 2023434425
Apr 2023363733
May 2023454538
Jun 2023394035
Jul 2023535336
Aug 2023454522
Sep 2023474716
Oct 2023696940
Nov 2023535325
Dec 2023444413
Jan 2024353619
Feb 2024434320
Mar 2024494955
Apr 20245656299
May 2024292916
Jun 2024606228
Jul 2024717432
Aug 2024404033
Sep 2024303019
Oct 2024777730
Nov 2024596124
Dec 2024646719
Jan 2025474717
Feb 2025595924
Mar 2025323323
Apr 2025545428
May 2025383823
Jun 2025252514
Jul 2025110
Aug 2025110
Total333733831864